MRK- I think it shows excellent value here at the level. Vioxx represented about 10% of revenues. MRK looks to have a drug near approval that will replace it. The dividend will put a floor in on the fall. (4.5%). Lawsuits...they take years. MRK is in a good industry with strong demographics to support it in the future.
I hope that PFE doesn't mess with Celebrex..I would have a hard time getting by without that.
Market Data 
Markets 
AI
